Venture capital firm BC Partners has reached an agreement for Goldman Sachs Alternatives to acquire a majority stake in Synthon, a Netherlands-based company. BC Partners will maintain a minority stake to aid in Synthon's future growth.

While the specific terms of the deal were not disclosed, sources cited by the Financial Times indicated that the enterprise value exceeds 2 billion euros (approximately $2.1 billion).

Synthon is known for developing and manufacturing generic versions of complex drugs, with a portfolio that includes treatments for cancer, cardiovascular diseases, and multiple sclerosis.

This acquisition highlights the ongoing interest in the pharmaceutical sector, particularly in companies that specialize in generics. The deal is expected to bolster Synthon's capabilities and market presence, leveraging Goldman Sachs' resources and expertise.

For those interested in more detailed coverage of the pharmaceutical and biotechnology industries, registration for exclusive content is available. Subscribers can access features, interviews, and analyses from industry experts, along with daily news updates.

In summary, the acquisition of Synthon by Goldman Sachs Alternatives marks a significant move in the generics market, with BC Partners continuing to play a role in the company's growth trajectory.